Clonal hematopoiesis is associated with risk of severe Covid-19.
Adolescent
Adult
Aged
Aged, 80 and over
COVID-19
/ etiology
Child
Child, Preschool
Clonal Hematopoiesis
/ genetics
Cohort Studies
Female
Hematopoietic Stem Cells
/ virology
Humans
Infant
Infant, Newborn
Male
Middle Aged
Mutation
/ immunology
Neoplasms
/ genetics
Risk Factors
SARS-CoV-2
Severity of Illness Index
Journal
Nature communications
ISSN: 2041-1723
Titre abrégé: Nat Commun
Pays: England
ID NLM: 101528555
Informations de publication
Date de publication:
13 10 2021
13 10 2021
Historique:
received:
13
04
2021
accepted:
10
09
2021
entrez:
14
10
2021
pubmed:
15
10
2021
medline:
30
10
2021
Statut:
epublish
Résumé
Acquired somatic mutations in hematopoietic stem and progenitor cells (clonal hematopoiesis or CH) are associated with advanced age, increased risk of cardiovascular and malignant diseases, and decreased overall survival. These adverse sequelae may be mediated by altered inflammatory profiles observed in patients with CH. A pro-inflammatory immunologic profile is also associated with worse outcomes of certain infections, including SARS-CoV-2 and its associated disease Covid-19. Whether CH predisposes to severe Covid-19 or other infections is unknown. Among 525 individuals with Covid-19 from Memorial Sloan Kettering (MSK) and the Korean Clonal Hematopoiesis (KoCH) consortia, we show that CH is associated with severe Covid-19 outcomes (OR = 1.85, 95%=1.15-2.99, p = 0.01), in particular CH characterized by non-cancer driver mutations (OR = 2.01, 95% CI = 1.15-3.50, p = 0.01). We further explore the relationship between CH and risk of other infections in 14,211 solid tumor patients at MSK. CH is significantly associated with risk of Clostridium Difficile (HR = 2.01, 95% CI: 1.22-3.30, p = 6×10
Identifiants
pubmed: 34645798
doi: 10.1038/s41467-021-26138-6
pii: 10.1038/s41467-021-26138-6
pmc: PMC8514469
doi:
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
5975Subventions
Organisme : NCI NIH HHS
ID : K08 CA241318
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States
Organisme : U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI)
ID : K08CA241318
Commentaires et corrections
Type : UpdateOf
Informations de copyright
© 2021. The Author(s).
Références
BMC Cancer. 2019 Aug 28;19(1):848
pubmed: 31462227
J Clin Oncol. 2020 Nov 20;38(33):3914-3924
pubmed: 32986528
Nat Med. 2021 Jun;27(6):1012-1024
pubmed: 34099924
J Clin Oncol. 2020 Oct 20;38(30):3538-3546
pubmed: 32795225
Stem Cell Reports. 2020 Apr 14;14(4):551-560
pubmed: 32220332
Nature. 2018 Jul;559(7714):350-355
pubmed: 29995854
J Korean Med Sci. 2020 Aug 03;35(30):e280
pubmed: 32743995
Cell Stem Cell. 2018 Dec 6;23(6):833-849.e5
pubmed: 30526882
Nature. 2020 Oct;586(7831):763-768
pubmed: 33057201
N Engl J Med. 2020 Apr 30;382(18):1708-1720
pubmed: 32109013
Nature. 2018 May;557(7706):580-584
pubmed: 29769727
Blood. 2017 Aug 10;130(6):742-752
pubmed: 28483762
Nature. 2020 Aug;584(7819):130-135
pubmed: 32581364
Nat Genet. 2020 Nov;52(11):1219-1226
pubmed: 33106634
Lancet. 2020 Jun 20;395(10241):1907-1918
pubmed: 32473681
JAMA. 2020 Apr 14;323(14):1335
pubmed: 32181795
BMJ. 2020 May 22;369:m1966
pubmed: 32444366
JMIR Med Inform. 2019 Nov 29;7(4):e14325
pubmed: 31553307
N Engl J Med. 2017 Jul 13;377(2):111-121
pubmed: 28636844
J Am Coll Cardiol. 2018 Feb 27;71(8):875-886
pubmed: 29471939
Int J Infect Dis. 2020 May;94:91-95
pubmed: 32173574
Circulation. 2020 Jan 14;141(2):124-131
pubmed: 31707836
Hemasphere. 2020 Aug 10;4(4):e453
pubmed: 32885145
Cancer Lett. 2019 Dec 28;467:1-8
pubmed: 31563562